{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.98","upperLimit":"5.72","value":"5.49"},{"comment":"Median duration of response was not reached as only 2 of the 12 participants with a qualifying response had subsequent disease progression or death due to any cause at the time of the analysis.","groupId":"OG001","lowerLimit":"4.60","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Duration of response was defined as the time between the date of the earliest qualifying response and the date of disease progression or death due to any cause. Duration of response was calculated only for participants who had a best overall response of Complete Response or Partial Response and was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"OG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants randomized by September 22, 2010 and with a best overall confirmed response of complete response or partial response.","reportingStatus":"POSTED","timeFrame":"From randomization (initiated in January 2010) until December 30, 2010.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}